KRAS-Targeted Drug Sparks Immune Defense to Prevent Pancreatic Cancer in High-Risk People
TL;DR Summary
Johns Hopkins researchers report that an experimental KRAS-targeting drug was safe in a phase 1 trial of 20 people at high risk for pancreatic cancer and successfully activated KRAS-specific T-cells in 90% of participants, with immune responses persisting for about two years; while no cancers or high-risk lesions progressed during follow-up, the small study was not designed to prove prevention.
- Experimental Drug Generates Immune Response Against Pancreatic Cancer in People at High Risk Good News Network
- mRNA immunotherapy developed at UMass Chan eliminates pancreatic tumors in half of treated mice News Link Live
- Maen Abdelrahim։ Promising Personalized Vaccine in the Pipeline for TNBC and Pancreatic Cancer Oncodaily
- New Pancreatic Cancer Vaccine Shows Promise in Prevention EMJ
- An early shot at stopping PDAC Nature
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
40 min
vs 41 min read
Condensed
99%
8,129 → 60 words
Want the full story? Read the original article
Read on Good News Network